Industry experts dedicated to changing the world of cancer detection and saving more patients’ lives

The AOA Dx team is transforming women’s health

The AOA Dx founding team has worked together for over a decade at two successful women’s health diagnostic startups, both resulting in strategic exits. With more than 30 years of experience bringing products from concept to commercialization across global markets, they’ve assembled a unique team of experts in the field who are passionate about changing the world of oncology and women’s health.

Founders

Oriana Papin-Zoghbi

Position: Chief Executive Officer & Co-Founder
Categories: Founders

Oriana is a visionary leader in the field of women’s health and diagnostics. Recently honored in Inc’s 2022 Top 100 Female Founders for her work in ovarian cancer diagnosis, Oriana brings a wealth of knowledge and expertise bringing disruptive diagnostics to market and changing the landscape of clinical practice. Oriana is passionate about entrepreneurship and problem solving and hopes to use these skills to revolutionize early cancer detection, particularly in cancers that disproportionately affect women.

Oriana has global experience creating and leading organizations resulting in successful strategic exits. Prior to AOA, she led teams at early-stage startups and large life sciences companies. Oriana has a track record of developing a highly productive culture and turning visions into reality. She has a proven technical record of creating market entry strategies and product launches in new markets, including launching nationwide HPV screening in East Africa and novel diagnostics in maternal fetal medicine, oncology and infectious diseases.

As CEO of AOA, her dedication and work have earned her numerous awards and recognition, including the Massachusetts Life Sciences Center MassNextGen Award, The Eddies People’s Choice Award and The Wave Summit’s Emerging Women Founder in Bio Award.

Oriana holds a degree from Boston University in Economics and International Relations, and she has experience both living and working in various geographies.

Oriana Papin-Zoghbi

Chief Executive Officer & Co-Founder

Alex Fisher

Position: Chief Operating Officer & Co-Founder
Categories: Founders

Alex is a passionate and dedicated business leader with a track record of launching UK medical device and diagnostics sales companies. He has​ extensive experience priming markets, launching products and driving early product sales.​

In most recent roles, Alex has been committed to commercializing and launching innovative, disruptive products through his own businesses across European healthcare markets with a primary focus on obstetrics and gynecology.​​

Alex works closely with Oriana, ensuring strategies relating to finance, accounting, legal and fundraising are executed in a timely manner. On a daily basis, Alex ensures AOA’s operations are running smoothly and efficiently.

Alex has a degree and MSc from the University of Southampton and University College London.

Alex Fisher

Chief Operating Officer & Co-Founder

Anna Jeter

Position: Chief Regulatory Officer & Co-Founder
Categories: Founders

Anna is an innovator and a dynamic business leader with a passion for advancing healthcare through world-class diagnostics.​ As the Chief Reglatory Officer of AOA, she is pioneering the development of the groundbreaking GlycoLocateTM platform for early cancer detection by utilizing tumor marker gangliosides and AI to solve some of the most difficult challenges in diagnostics today.

Anna was named to Inc. Magazine’s 2022 Female Founders 100 List. She brings a wealth of experience to AOA having overseen the inclusion of multiple products into national and pan-European guidelines, and she has experience with US FDA submissions for 510(k), PMA, and CLIA LTD regulatory routes.​

Anna has a unique global perspective on healthcare having led teams launching paradigm changing diagnostics in women’s health in Europe, the Middle East, Latin America and Asia.

Anna Jeter

Chief Regulatory Officer & Co-Founder

Team

Adele Blackler, Ph.D.

Position: Vice President of Platform Development
Categories: Team

Adele has extensive experience in mass spectrometry, oncology liquid biopsy tests and clinical proteomic applications. For the past decade, she has worked at multiple diagnostic companies developing multiplex biomarker tests to support therapeutic decisions for solid tumor treatment, including lung, colorectal and breast cancer. She has worked on single site Laboratory Developed Tests using both proteomic and genomic platforms and Clinical Trial Assays as companion diagnostics for guiding lung cancer therapy.

Adele received her bachelor’s in chemistry from the Colorado school of mines and received her Ph.D. from the University of Colorado, at Anschutz, where she developed high-throughput proteomic methods for membrane proteins. Her post-doctoral fellowship was at the National Cancer Institute developing methods to combine high throughput protein analysis with tissue microdissection.

As Vice President of Platform Development, Adele oversees development of new assays for the detection and quantitation of gangliosides to identify disease signatures.

Adele Blackler, Ph.D.

Vice President of Platform Development

Elizabeth Yarber

Position: Senior Director of Clinical Operations
Categories: Team

Elizabeth is a clinical research professional specializing in the management of clinical operations, quality, and regulatory oversight of global clinical trials in multiple therapeutic areas in biopharmaceutical, medical device and diagnostics.​

Elizabeth has extensive experience in all phases of clinical trials that allowed market access for strategic business initiatives. She is Project Management certified through PMI and has been involved in the clinical trial process from development to regulatory approval applying a strong focus on risk and quality oversight.

As Director of Clinical Operations, Elizabeth has overall responsibility for leading AOA’s clinical study operations.

Elizabeth holds an undergraduate degree in Organizational Leadership and a MSc. in Health Outcomes Research from St. Louis University.

Elizabeth Yarber

Senior Director of Clinical Operations

Andrea Cioffi

Position: Director of Business Operations
Categories: Team

Andrea is a passionate leader who excels at scaling up systems and solutions to create positive outcomes for community stakeholders.

Having graduated from the Boston University Questrom School of Management with a degree in Marketing, she was a 2009 Teach for America Corps member, serving in Chelsea MA.

After spending 13 years working in charter and turnaround schools as a school leader she has pivoted to ensuring behind the scenes operations at AOA Dx run smoothly in order to accomplish our mission critical goals.

While she has worked for AOA part time since 2020, she is excited to support the team full time in finance, HR, marketing, and project management.

Andrea Cioffi

Director of Business Operations

Jeanne Jones

Position: Senior Clinical Project Manager
Categories: Team

Jeanne has 25+ years of clinical research experience working from the site, CRO and sponsor perspectives. Before joining the AOA Dx team as the Senior Clinical Project Manager she worked as a contract Senior Project Manager for various clinical and device trials and served as a consultant to Mary Crowley Cancer Research in expanding their clinical sites.  Prior to this, Jeanne was the Vice President of Clinical Operations at Mary Crowley Cancer Research an Oncology phase I clinical trial site, Vice President of Patient Management Program and Program Development for the Multiple Sclerosis Franchise, and Sr. Director of Clinical Operations for Oncology at Genzyme. At US Oncology she served as Sr. Director of Clinical Operations then then as Vice President of Development. While at Mary Crowley, Jeanne successfully provided oversight to over 100 early phase clinical trials working with over 50 pharmaceutical and CRO’s.  Jeanne successfully led a global team to completion of a phase III trial for subjects with CLL and with a pivotal phase II trial in multiple sclerosis at Genzyme.  During her time at US Oncology she developed, secured, and managed strategic partnerships with multiple large pharmaceutical companies and provided oversight to several oncology disease programs working closing with the physician in the development of a clinical trial portfolio for the network.    Jeanne graduated from the University of Iowa with a Bachelor of Science in nursing and then received her Master of Science in nursing and administration from the University of Nebraska in Omaha, Ne.

Since starting her career in research, she has worked on all phase of clinical trials from Phase I to III and from all aspects of the industry from the site, CRO and pharmaceutical or biotechnology.

Jeanne Jones

Senior Clinical Project Manager

Michael Matthews

Position: Senior Clinical Trial Specialist
Categories: Team

Michael joins AOA Dx as a Senior Clinical Trial Specialist dedicated to transforming women’s health by establishing and maintaining strong rapport with site staff participating in AOA Dx’s groundbreaking OVERT clinical study. Utilizing his extensive experience as both a clinical research coordinator and monitor, Michael is motivated to encourage trial engagement while increasing the efficacy of and diversity within enrollment to the OVERT study.

As a past Division III varsity swimmer and undergraduate of Washington University in St. Louis, Michael is familiar with finding comfort in uncomfortable situations. With a BA in Biology and a brief stint as an Emergency Medical Technician, he has built a strong foundation in complex scientific and medical processes, and he consistently seeks out opportunities to improve the efficiency and output of those processes.

Michael is driven by AOA Dx’s vision and mission and strives to contribute to a growing global impetus toward advancing preventive healthcare and accessibility to early screening and diagnostics. Outside of work, Michael enjoys walking his yellow lab Murph, competing in triathlons, and writing music.

Michael Matthews

Senior Clinical Trial Specialist

Robert Law, Ph.D.

Position: Senior Immunoassay Scientist
Categories: Team

Robert is an industrious molecular and cell biology expert with more than a decade of experience conducting research in the areas of biopharmaceutical engineering, genome editing, and cancer cell biology. He has utilized his proficiency in these areas to execute product development strategies within the gene editing space in addition to spearheading research efforts to delineate complex cell signaling pathways for the identification of diagnostic and therapeutic targets to combat cancer. His work has resulted in several publications in Science Advances, Science Signaling, Journal of Cell Biology, and Cancer Research.

As an innovative and dynamic scientist, Robert is committed to solving challenging problems centered around cancer diagnostics and prevention. At AOA Dx, he is using his skills and expertise to develop AOA’s ovarian cancer diagnostic test in conjunction with expanding the GlycoLocate™ platform to enable the detection of additional cancer targets.

Having earned his Ph.D. from Johns Hopkins University in Chemical and Biomolecular Engineering, Robert also holds a B.S. from The Ohio State University in the same discipline graduating “With Research Distinction”.

Robert Law, Ph.D.

Senior Immunoassay Scientist

Adam Cadwallader

Position: Laboratory Manager

Categories: Team

Adam possesses extensive expertise in sugar biochemistry, cancer biology, and laboratory management. Throughout his career, he has dedicated his time to unraveling the mysteries of how glycobiology influences development, cancer, and regeneration. Adam’s commitment to creative problem-solving has played a crucial role in assisting fellow scientists in their pursuits. Having earned his bachelor’s degree from Duquesne University and his Ph.D. from the University of Utah, where he explored the regulation of biological development by sugars, Adam continued his research during his post-doctoral fellowship at the UCSD Glycobiology Core and a research fellowship at CU Boulder. His focus remained on understanding the role of sugars in organ regeneration. At Enveda Biosciences, he was entrusted with establishing a comprehensive laboratory capable of handling the complexities of the natural world. In his role as Laboratory Manager, Adam will not only oversee various aspects of the Denver facility and laboratory operations but will also contribute to the development of new assays.

Adam Cadwallader

Laboratory Manager

Rachel Culp-Hill, Ph.D.

Position: Mass Spectrometry Scientist
Categories: Team

Rachel is an accomplished expert in metabolomics with over 10 years of mass spectrometry experience. Her previous research focused on studying metabolic alterations in various disease states, including acute myeloid leukemia, Down Syndrome, sickle cell disease, breast cancer, and hemorrhagic shock. Her groundbreaking work on understanding the complex metabolome of acute myeloid leukemia stem cells and other cancers has been published in scientific journals such as Nature Medicine, Nature Cancer, Cell, Cancer Cell, Cell Stem Cell, Blood, and more.

At AOA Dx, Rachel dedicates her expertise to validating a diagnostic test for ovarian cancer and expanding the GlycoLocateTM platform to detect additional cancer targets. Her commitment to cancer diagnostics and prevention fuels her drive to solve challenging problems in the field.

Rachel earned her Ph.D. in Biochemistry from the University of Colorado Anschutz Medical Campus and holds an M.Sc. in Microbiology from the University of Florida, along with a B.S. in Biochemistry and Molecular Biology from Michigan State University. With her multidisciplinary knowledge, scientific acumen, and proven track record, Rachel continues to push the boundaries of cancer research, contributing to advancements in detection and treatment methods.

Rachel Culp-Hill, Ph.D.

Mass Spectrometry Scientist

Mattie Goldberg

Position: Project Manager

Categories: Team

Committed to operational excellence, Mattie thrives in devising data-centric, scalable systems using Lean Six Sigma techniques. Her strategic focus is on enhancing efficiency and data utility for continuous improvement.

Mattie’s educational path led her from working as a cook in James Beard Award-winning kitchens to earning a Bachelor’s in Biotechnology Engineering from the University of Houston, graduating Magna Cum Laude. Her studies integrated service expertise with a strong foundation in biological and process engineering.

Her swift advancement to Process Improvement Manager involved redefining laboratory workflows and developing executive dashboards for operational oversight at a national pre-donor transplant and product testing organization. As a Project Manager, she now directs R&D activities, focusing on achieving key development milestones and ensuring efficient, quality-driven product launches.

Mattie Goldberg

Project Manager

Enkhtuya Radnaa, Ph.D.

Position: Immunoassay Scientist

Categories: Team

Dr. Enkhtuya Radnaa, MS., Ph.D., is an experienced Molecular and Cellular Biology Scientist with a decade-long journey in the field. Her cancer-related research journey began at the Cancer Research Institute, Kanazawa University, Japan, where she earned her Ph.D. and pursued postdoctoral research. Expanding upon her expertise in cancer research, Dr. Enkhtuya Radnaa embarked on a new phase of her career in obstetrics and gynecology within the University of Texas Medical Branch (UTMB) research division. As a faculty member specializing in molecular and cellular biology, she took the lead on groundbreaking projects. Notably, she was instrumental in developing immortalized cell lines derived from human placental tissues and conducted intricate gene manipulations within these cell lines. These cell lines have proven to be invaluable assets, playing a pivotal role in advancing organ-on-chip-based research initiatives. Dr. Enkhtuya Radnaa’s efforts in this regard have been supported by multiple NIH-funded grants, including those provided by NCATs and the Superfund research programs. Her innovative work has significantly contributed to the ongoing progress of research at the intersection of molecular biology and women’s health, helping to advance our understanding of critical aspects of human reproduction and development. Her research in understanding the molecular mechanisms underlying preterm birth studies garnered recognition. Dr. Enkhtuya Radnaa received the prestigious “Best New Investigator” award in 2022 from the Society for Reproductive Investigation for her contributions to furthering the Society’s objectives in women’s health. Enkhtuya’s unwavering dedication to scientific exploration is evident in her contributions to publications, including those featured in Science Advances, Lab on a Chip, Clinical Science, and Biology of Reproduction journals.

Enkhtuya Radnaa, Ph.D.

Immunoassay Scientist

Megan Miller-Awe

Position: Laboratory Technician

Categories: Team

Megan is a jack-of-all trades in the laboratory, with experience in veterinary parasitology, wildlife disease, pathology, hematology, and oncology. At AOA Dx, she uses her technical expertise to support scientists across the organization in our mission to Transform Women’s Health. Megan earned her Masters in Comparative and Experimental Medicine from the University of Tennessee Knoxville and her Bachelors in Ecology and Evolutionary Biology from the University of Colorado Boulder. When she is not in the lab, she spends her time snowboarding, rock climbing, running, and cuddling with her cats.

Megan has been published in Blood and Journal of Leukocyte Biology.

Megan Miller-Awe

Laboratory Technician

Maria Wong

Position: Laboratory Technician

Categories: Team

Maria is a dedicated scientist with over 10 years experience working in both academic and pre-clinical research. She has worked in oncology, renal, and pulmonary fields. She will use her skills to support AOA Dx’s platform development.

She earned her Bachelor’s and Master’s degree in Biology at University of Colorado – Denver and is currently enrolled in the IU Kelley School of Business MBA program. When not in the lab, she is overlanding with her husband and three dogs.

Maria Wong

Laboratory Technician

Lindsey Kemp

Position: Clinical Trial Associate

Categories: Team

Lindsey is a Clinical Trial Associate at AOA Dx, driven by a profound passion to revolutionize women’s healthcare and support the team’s ongoing clinical trial.

With over five years of experience in biotech and clinical research, Lindsey comes with a rich background in both R&D and clinical settings. She has held pivotal roles at esteemed organizations such as Moderna Therapeutics, Gritstone Bio, and University of Colorado where she’s gained expertise in immunology and oncology. She joins the team with knowledge in regulatory documentation, operational process design, and management of clinical trial software, data, samples, and sites.

Lindsey graduated with a Bachelor of Science degree in Chemistry and a minor in Neuroscience, providing her with a solid scientific foundation.  At AOA Dx, Lindsey is on a mission to support the organization’s vision of bringing early detection diagnostic tests for ovarian cancer to women. Through her role in the clinical team, Lindsey will support site recruitment and retention, management of samples and kits, and oversight of regulatory compliance. She aims to leverage her diverse skill set and industry knowledge to make a meaningful impact in women’s lives.

Outside of her professional pursuits, Lindsey loves to get out in nature. Often hiking and camping with her dogs. Lindsey is also deeply passionate about holistic health and wellness. With certifications in medicinal herbalism and culinary arts. She enjoys concocting herbal remedies or experimenting with new culinary creations. Both in and out of the office, Lindsey exemplifies her commitment to promoting health and well-being.

Lindsey Kemp

Clinical Trial Associate

Board Members

Oriana Papin-Zoghbi

Position: CEO and Board Member
Categories: Board

Oriana is a visionary leader in the field of women’s health and diagnostics. Recently honored in Inc’s 2022 Top 100 Female Founders for her work in ovarian cancer diagnosis, Oriana brings a wealth of knowledge and expertise bringing disruptive diagnostics to market and changing the landscape of clinical practice. Oriana is passionate about entrepreneurship and problem solving and hopes to use these skills to revolutionize early cancer detection, particularly in cancers that disproportionately affect women.

Oriana has global experience creating and leading organizations resulting in successful strategic exits. Prior to AOA, she led teams at early-stage startups and large life sciences companies. Oriana has a track record of developing a highly productive culture and turning visions into reality. She has a proven technical record of creating market entry strategies and product launches in new markets, including launching nationwide HPV screening in East Africa and novel diagnostics in maternal fetal medicine, oncology and infectious diseases.

As CEO of AOA, her dedication and work have earned her numerous awards and recognition, including the Massachusetts Life Sciences Center MassNextGen Award, The Eddies People’s Choice Award and The Wave Summit’s Emerging Women Founder in Bio Award.

Oriana holds a degree from Boston University in Economics and International Relations, and she has experience both living and working in various geographies.

Oriana Papin-Zoghbi

CEO and Board Member

Surbhi Sarna

Position: Board Member
Categories: Board

Surbhi Sarna is the founder and former CEO of nVision medical, a medical device company that, to date, is the only device cleared by the FDA to collect cells from the fallopian tube for the detection of ovarian cancer. Having led the company from inception, nVision Medical was acquired by Boston Scientific in 2018 for $275m.

Most recently Surbhi became Y Combinator’s first-ever partner for healthcare and biotech, and she currently sits on the board of Penumbra, Progenity, Astia, Draper University and the Harker School. Surbhi has extensive experience with early product development, funding, clinical trials and commercialization.

Surbhi Sarna

Board Member

John Friedman

Position: Board Member
Categories: Board

John Friedman has been the Founding and Managing Partner of Easton Capital Investment Group for approximately 20 years. He also serves as an Advisor to Good Growth Capital and Senior Advisor to Gore Range Capital. Prior to founding Easton Capital, John was the founder and Managing General Partner of Security Pacific Capital Investors. Security Pacific Capital Investors was a $200 million private equity fund, affiliated with the 5th largest US bank. Before he joined Security Pacific, John was a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., where he spent eight and a half years. Previously, John was an attorney with Sullivan and Cromwell. During his career, he has invested in more than 100 transactions.

John currently serves on the boards of AOA Dx, Trellis Bioscience, Sequella, Sensoriant, AdipoPharma, and Vantiq Inc. John previously served as a board observer of Claret Medical and Paradigm Diagnostics prior to their acquisition, and as a board member of Conor Medsystems, Acorda (NASDAQ: ACOR), bluebird bio (NASDAQ: BLUE), and Cardiovascular Systems (NASDAQ: CSII), among others. In each case, he had been a founding, lead, or co-lead investor in that company.

Throughout his career John has been heavily involved with the New York medical science community. He previously served as Chairman of the Columbia University Medical Center’s Health Sciences Advisory Council and Co-Chairman of the President’s Council at the Cold Spring Harbor Laboratory. John is also on the Board of Trustees of the New Museum and co-founded Comverse Technology, which became the largest mobile message management company in the world.

John holds a Bachelor of Arts degree in History from Yale College, where he graduated magna cum laude and was a member of Phi Beta Kappa. John also holds a Juris Doctor degree from Yale Law School.

John Friedman

Board Member

Advisors

Prof. Uri Saragovi, PhD

Position: Inventor
Categories: Advisors

Dr. Saragovi is a passionate and world-leading scientist in the area of Translational Medicine.

Dr. Saragovi has published over 200 publications and 21 patents, primarily focusing translational medicine. More recently Dr. Saragovi has focused on the targeting of gangliosides, which are used clinically for cancer diagnosis, prognosis, and therapy.

Dr. Saragovi based at McGill University and Lady Davis Institute at the Jewish General Hospital, Montreal.

Prof. Uri Saragovi, PhD

Inventor

Elizabeth Garner, MD

Position: Clinical Advisor
Categories: Advisors

Elizabeth Garner, MD, MPH has over a decade of pharmaceutical development experience. She also has deep expertise in clinical trial design and execution. She has held roles of increasing strategic responsibility in large and small companies, including ObsEva SA, Merck, Abbott (AbbVie), Myriad Genetics, and Agile Therapeutics. In addition to Pharm-Olam, she is also on the Boards of the Drug Information Association (DIA) and the American Medical Women’s Association (AMWA), and she was a 2019 awardee of the PharmaVoice 100 most inspiring individuals in the life-sciences industry.

Dr. Garner is currently the Chief Scientific Officer at Ferring Pharmaceuticals, a biopharmaceutical company that focuses on the development of innovative products in the areas of reproductive medicine and maternal health, urology and gastroenterology. Dr. Garner received joint MD and MPH degrees from Harvard Medical School and the Harvard School of Public Health. She was trained in obstetrics and gynecology at Brigham and Women’s/Massachusetts General Hospitals and completed a fellowship in gynecologic oncology at Brigham and Women’s and Dana Farber Cancer Institute.

Elizabeth Garner, MD

Clinical Advisor

Kevin Elias, MD

Position: Clinical Advisor
Categories: Advisors

Dr. Kevin Elias is an experienced physician-scientist with a demonstrated history of success in translational medicine and advanced oncologic care. He has years of experience in Medical Education, Clinical Trials & Healthcare Leadership for gynecologic oncology and early cancer detection. Graduating from Harvard College and Vanderbilt University School of Medicine, he completed his residency in OB/GYN at Brigham and Women’s Hospital and fellowships is Gynecologic Oncology and Anesthesia Critical Care Medicine at Brigham and Women’s Hospital. Additionally, he conducted post-doctoral research at Dana-Farber Cancer Institute in molecular biology and MIT in cancer nanotechnology. He is currently an active practicing physician and Director of the Gynecologic Oncology Laboratory at Brigham and Women’s Hospital.

Kevin Elias, MD

Clinical Advisor

Amy P.N. Skubitz, Ph.D.

Position: Clinical Advisor
Categories: Advisors

Amy P.N. Skubitz, Ph.D. is a Professor in the Department of Laboratory Medicine and Pathology at the University of Minnesota (UM) and an Adjunct Professor in the Department of Obstetrics, Gynecology, and Women’s Health. Dr. Skubitz serves as the Director of the Ovarian Cancer Early Detection Program (OCEDP) at the UM.

Her research interests include the progression and recurrence of ovarian cancer, which involves its genetic profile and the discovery of new biomarkers by mass spectrometry-based proteomics using a wide variety of biospecimens. Her research studies represent an approach toward understanding the molecular mechanisms modulating the phenotypic behavior of cancer cells with the ultimate goal of designing biomarkers and/or biopharmaceuticals for therapeutic use in cancer.

As a faculty member at the UM for the past 30 years, Dr. Skubitz’s research has been continually funded from a variety of sources. She has published over 125 manuscripts in the field of cancer. She has overseen and supervised many projects with collaborators at the UM, nationally, and internationally.

She established the UM’s Tissue Procurement Facility and served as the Director or Assistant Director for 15 years. She has been a member of the International Society for Biological and Environmental Repositories since 1999, and served on the Education and Training Committee for 6 years.

She has been a mentor to many faculty, postdoctoral fellows, graduate students, undergraduates, and technicians who have performed research projects in her laboratory.

Amy P.N. Skubitz, Ph.D.

Clinical Advisor